HMN 2025: How Hormone is discovered to suppress immune cells, permitting cancer to evade detection

Researchers at UT Southwestern Medical Center have found how a hormone interacts with a receptor on the floor of immune cells to defend cancer cells from the physique’s pure defenses.

The findings, revealed in Nature Immunology, may result in new immunotherapy approaches for treating cancer in addition to potential remedies for inflammatory problems and neurologic illnesses.

“Myeloid cells are among the many first group of immune cells recruited to tumors, however in a short time these tumor-fighting cells flip into tumor-supporting cells. Our study means that receptors on these myeloid cells get stimulated by this hormone and find yourself suppressing the immune system,” stated Cheng Cheng “Alec” Zhang, Ph.D., Professor of Physiology and a member of the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern. Dr. Zhang co-led the research with first creator Xing Yang, Ph.D., a postdoctoral researcher within the Zhang Lab.

Current immunotherapies, equivalent to immune checkpoint inhibitors, are efficient for less than about 20–30% of cancer sufferers, Dr. Zhang stated, suggesting that there are a number of ways in which cancers evade assault from the immune system.

Several years in the past, researchers within the Zhang Lab learning cancer-fighting immune cells known as myeloid cells recognized an inhibitory receptor known as LILRB4. Stimulating this receptor blocked the myeloid cells’ capacity to assault tumors.

Dr. Zhang, Dr. Yang and their colleagues then did a genome-wide display screen of all proteins that may work together with LILRB4.

A promising hit was a hormone known as SCG2. Although researchers have prompt that SCG2 performs a task in immune response, its operate and receptor had been unknown.

Laboratory experiments confirmed that SCG2 binds to LILRB4, kicking off a signaling cascade that turned off the cancer-fighting skills of myeloid cells and inhibited their capacity to recruit cancer-fighting T cells to tumors.

In mice genetically altered to specific the human type of LILRB4, injected cancer cells that produced SCG2 grew quickly as tumors. Treating these mice with an antibody that blocks LILRB4 considerably slowed cancer progress, as did artificially ridding the animals’ our bodies of SCG2.

Together, these experiments recommend that interactions between LILRB4 and SCG2 permit cancer to develop unchecked by myeloid cells, T cells, and doubtlessly different immune cell varieties.

Dr. Zhang prompt that disrupting this interplay may sometime supply a brand new immunotherapy choice to deal with cancer.

Conversely, as a result of this interplay neutralizes myeloid cells’ immune exercise, delivering further SCG2 could possibly be a promising therapy for autoimmune or inflammatory problems spurred by myeloid cells. Dr. Zhang and his colleagues plan to analyze each concepts in future research.